Astrazeneca (AZN) Long-Term Investments (2009 - 2026)

Astrazeneca's Long-Term Investments history runs 18 years deep, the most recent figure standing at $306.0 million for Q1 2026.

• In Q1 2026, Long-Term Investments rose 13.33% year-over-year to $306.0 million; the TTM figure through Mar 2026 stood at $306.0 million (up 13.33% YoY), while the FY2025 annual figure was $302.0 million, up 12.69% from the prior year.
• Long-Term Investments was $306.0 million for Q1 2026 at Astrazeneca, up from $302.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $1.1 billion in Q4 2022 to a low of -$13.0 million in Q1 2024.
• Historically, Long-Term Investments has averaged $218.4 million across 5 years, with a median of $264.0 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Long-Term Investments slumped 120.75% in 2023, then surged 2736.36% in 2024.
• A 5-year view of Long-Term Investments shows it stood at $1.1 billion in 2022, then tumbled by 86.21% to $147.0 million in 2023, then surged by 82.31% to $268.0 million in 2024, then increased by 12.69% to $302.0 million in 2025, then climbed by 1.32% to $306.0 million in 2026.
• The last three Long-Term Investments figures came in at $306.0 million (Q1 2026), $302.0 million (Q4 2025), and $296.0 million (Q3 2025), per Business Quant data.